Est. 2003 · Dallas, Texas

Investing in Private and Public Companies

Colt Ventures is a diversified investment firm that invests in a variety of sectors and was founded in 2003. The firm is headquartered in Dallas, TX.

2003Founded in Dallas
250+Companies backed
30+Years investing
$15MUp to per deal
Public Portfolio Companies · Live Prices

Market data provided by TradingView and may be delayed. For informational purposes only.

Who We Are

Decades of investing experience, focused on meaningful impact.

Colt Ventures is an investment firm built on decades of investing experience across a variety of sectors and focused on investments that have a meaningful and measurable impact on people’s lives.

By remaining targeted and narrow, we are able to source and evaluate hundreds of deals each year across the private and public markets. We leverage our proprietary network of innovators, seasoned executives, and blue-chip investors to identify the best opportunities with the highest potential for significant returns. We partner with our portfolio companies to provide a differentiated network of industry experts.

Portfolio

Companies we’ve backed

View full portfolio
Focus Areas

Where we invest

01

Biotechnology

02

Oil & Gas

03

Technology

04

Real Estate

05

Consumer & Retail

06

Financial Services

07

Special Situations

08

Institutional Managers

Our Principles

Built on a core set of principles

  1. Invest up to $15M per deal
  2. Focus on inefficient markets
  3. Back proven management teams with a track record of success
  4. Focus on significant value inflection points in the near term
  5. Look for a near-term liquidity horizon
Institutional Managers

Investing alongside aligned managers

In addition to our private and public portfolios, Colt also invests in institutional managers that are aligned with our focus sectors and investment principles.

Hedge FundsVenture Capital FundsPrivate Equity Funds
Milestones

Recent news from our portfolio

All news

BlossomHill Therapeutics prices upsized $150 million IPO

Read more

Odyssey Therapeutics prices upsized initial public offering

Read more

Alterome Therapeutics raises $132 million Series B led by Goldman Sachs Alternatives

Read more